Metabolic effects of hormone replacement therapy

Journal of the British Menopause Society

Volumn 10, Issue 4, 2004, Pages 157-161

  Stevenson, John C ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Arterial function; Coronary heart disease; Hormone replacement therapy; Lipids; Metabolic risk factors

Indexed keywords

BLOOD CLOTTING FACTOR 7; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE; DYDROGESTERONE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL; FIBRINOGEN; GESTAGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; NORGESTREL; TIBOLONE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG MECHANISM; FEMALE; GLUCOSE METABOLISM; GROUPS BY AGE; HORMONE SUBSTITUTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIPID METABOLISM; OXIDATIVE STRESS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; STROKE; THROMBOGENESIS; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS;

EID: 11244340639     PISSN: 13621807     EISSN: None     Source Type: Journal    
DOI: 10.1258/1362180042721049     Document Type: Review

References (58)

1. Zhang X, Patel A, Horibe H, et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003; 32: 563-572.
2. Gohlke-Barwolf C. Coronary artery disease - is menopause a risk factor? Basic Res Cardiol 2000; 95 (Suppl 1): 177-183.
3. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993; 98: 83-90.
4. de Aloysio D, Gambacciani M, Meschia M, et al. The effect of menopause on blood lipid and lipoprotein levels. The Icarus Study Group. Atherosclerosis 1999; 147: 147-153.
5. Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation 1993; 87: 1135-1141.
6. Li Z, McNamara JR, Fruchart JC, et al. Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes. J Lipid Res 1996; 37: 1886-1896.
7. Godsland IF, Stevenson JC. Insulin resistance: syndrome or tendency? Lancet 1995; 346: 100-103.
8. Walton C, Godsland IF, Proudler AJ, et al. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. Eur J Clin Invest 1993; 23: 466-473.
9. Proudler AJ, Felton CV, Stevenson JC. Ageing and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in postmenopausal women. Clin Sci 1992; 83: 489-494.
10. Ley CJ, Lees B, Stevenson JC. Sex- and menopause-associated changes in body-fat distribution. Am J Clin Nutr 1992; 55: 950-54.
11. Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynaecol Endocrinol 1997; 11: 341-55.
12. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88: 2404-2411.
13. Winkler UH. Menopause, hormone replacement therapy and cardiovascular disease: a review of haemostaseological findings. Fibrinolysis 1992; 6 (Suppl 3): 5-10.
14. Lindoff C, Petersson F, Lecander I, Martinsson G, Astedt B. Passage of the menopause is followed by haemostatic changes. Maturitas 1993; 17: 17-22.
15. Lieberman EH, Gerhard MD, Uehata A, et al. Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am J Cardiol 1996; 78: 1210-1214.
16. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 1995; 90: 244-248.
17. Blann AD, Amiral J, McCollum CN. Circulating endothelial cell/leucocyte adhesion molecules in ischaemic heart disease. Br J Haematol 1996; 95: 263-265.
18. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997; 96: 4219-25.
19. Zeitler H, Ko Y, Zimmermann C, et al. Elevated serum concentrations of soluble adhesion molecules in coronary artery disease and acute myocardial infarction. Eur J Med Res 1997; 2: 389-394.
20. Pfeilschifter J, Koditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002; 23: 90-119.
21. Whitcroft SI, Crook D, Marsh MS, et al. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. Obstet Gynecol 1994; 84: 222-226.
22. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001; 75: 898-915.
23. Kiran H, Kiran G, Ekerbicer HC, Kilinc M. Effects of intranasal estradiol treatment on serum lipoprotein(a) and lipids in hysterectomized women. Gynecol Obstet Invest 2004; 57: 191-95.
24. Palacios S. Pulsed estrogen therapy: relieving climacteric symptoms, preventing postmenopausal bone loss. Climacteric 2002; 5 (Suppl 2): 32-39.
25. van der Mooren MJ, de Graaf J, Demacker PN, de Haan AF, Rolland R. Changes in the low-density lipoprotein profile during 17 beta-oestradiol-dydrogesterone therapy in postmenopausal women. Metabolism 1994; 43: 799-802.
26. Stevenson JC, Oladipo A, Manassiev N, et al. Randomised trial of effect of transdermal continuous combined HRT on cardiovascular risk markers. Br J Haematol 2004; 124: 802-808.
27. Sack MN, Rader DJ, Cannon RO, Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994; 343: 269-70.
28. Westerveld HT, Kock LAW, van Rijn JM, et al. 17β-estradiol improves postprandial lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1995; 80: 249-253.
29. Spencer C, Crook D, Ross D, et al. A randomised comparison of the effects of oral versus transdermal 17β-oestradiol, each combined with sequential oral norethisterone acetate, on serum lipoprotein levels. Br J Obstet Gynaecol 1999; 106: 948-953.
30. Rymer J, Crook D, Sidhu M, et al. Effects of tibolone on serum concentrations of lipoprotein (a) in postmenopausal women. Acta Endocrinol 1993; 128: 259-262.
31. Crook D, Cust MP, Gangar KF, et al. Comparison of transdermal and oral estrogen/progestin hormone replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166: 950-955.
32. Stevenson JC. Metabolic effects of the menopause and oestrogen replacement. In: Barlow DH, ed. Baillière's Clinical Obstetrics and Gynaecology. The menopause: key issues, pp 449-67. London: Ballière Tindall, 1996.
33. Stevenson, JC. Lipid metabolism. In: Genazzani AR, ed. Hormone replacement therapy and cardiovascular disease, pp27-35. Carnforth: Parthenon Publishing, 2001.
34. Crook D, Godsland IF, Hull J, Stevenson JC. Hormone replacement therapy with dydrogesterone and oestradiol-17β: effects on serum lipoproteins and glucose tolerance. Br J Obstet Gynaecol 1997; 104: 298-304.
35. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199-208.
36. Spencer CP, Godsland IF, Cooper AJ, et al. Effects of oral and transdermal 17β-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism 2000; 49: 742-747.
37. Spellacy WN, Buhi WC, Birk SA. The effects of estrogens on carbohydrate metabolism: glucose, insulin and growth hormone studies on one hundred and seventy one women ingesting Premarin, mestranol and ethinyl estradiol for six months. Am J Obstet Gynecol 1972; 114: 378-392.
38. Morin-Papunen LC, Vauhkonen I, Ruokonen A, et al. Effects of tibolone and cyclic hormone replacement therapy on glucose metabolism in non-diabetic obese postmenopausal women: a randomized study. Eur J Endocrinol 2004; 150: 705-714.
39. Godsland IF, Gangar KF, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993; 42: 846-853.
40. Elkind-Hirsch KE, Sherman LD, Malinak R. Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure. J Clin Endocrinol Metab 1993; 76: 472-475.
41. Winkler UH. Menopause, hormone replacement therapy and cardiovascular disease: a review of haemostaseological findings. Fibrinolysis 1992; 6 (Suppl 3): 5-10.
42. Scarabin P-Y, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-432.
43. Winkler UH, Altkemper R, Kwee B, et al. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 2000; 74: 10-19.
44. Stevenson JC. Cardiovascular effects of estrogens. J Steroid Biochem Mol Biol 2000; 74: 387-393.
45. Koh KK, Cardillo C, Bui MN, et al. Vascular effects of estrogen and cholesterol lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999; 99: 354-60.
46. Koh KK, Bui MN, Mincemoyer R, Cannon RO. Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women. Am J Cardiol 1997; 80: 1505-1507.
47. Proudler AJ, Ahmed AIH, Crook D, et al. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet 1995; 346: 89-90.
48. Proudler AJ, Cooper A, Whitehead MI, Stevenson JC. Effect of oestrogen-only and oestrogen-progestogen replacement therapy upon circulating angiotensin I-converting enzyme activity in postmenopausal women. Clin Endocrinol 2003; 58: 30-35.
49. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002; 288: 980-987.
50. Post MS, van der Mooren MJ, Stehouwer CD, et al. Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomised, placebo-controlled trial. Thromb Haemostas 2002; 88: 605-610.
51. Koh KK, Ahn JY, Jin DK, et al. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study. Arterioscler Thromb Vasc Biol 2003; 23: 1889-1894.
52. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-868.
53. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degradating activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
54. Wingrove CS, Garr E, Godsland IF, Stevenson JC. 17b-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta 1998; 1406: 169-174.
55. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933-941.
56. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613.
57. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321-333.
58. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701-1712.